Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 6, 2022; 10(19): 6360-6369
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6360
Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis
Chou-Chin Lan, Po-Chun Hsieh, Chun-Yao Huang, Mei-Chen Yang, Wen-Lin Su, Chih-Wei Wu, Yao-Kuang Wu
Chou-Chin Lan, Chun-Yao Huang, Mei-Chen Yang, Wen-Lin Su, Chih-Wei Wu, Yao-Kuang Wu, Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan
Po-Chun Hsieh, Department of Chinese Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan
Author contributions: Lan CC, Hsieh PC, Huang CY, and Yang MC contributed to data curation; Lan CC and Hsieh PC contributed to formal analysis; Lan CC, Huang CY, Yang MC, Su WL, Wu CW, and Wu YK contributed to investigation; Lan CC and Wu YK contributed to conceptualization; Lan CC, Su WL, and Wu CW contributed to methodology; Lan CC, Hsieh PC, Huang CY, Yang MC, and Wu YK contributed to project administration; Lan CC and Wu YK contributed to funding acquisition; Lan CC, Wu YK, and Hsieh PC contributed to writing; Huang CY, Yang MC, and Wu YK contributed to validation; Lan CC and Hsieh PC contributed to the original draft; Lan CC contributed to review and editing; Wu YK contributed to supervision, visualization, review, and editing.
Supported by the Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. TCRD-TPE-108-RT-4(3/3; and No. TCRD-TPE-109-59.
Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yao-Kuang Wu, MD, Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan.drbfci@yahoo.com.tw
Received: January 23, 2022
Peer-review started: January 23, 2022
First decision: March 23, 2022
Revised: April 1, 2022
Accepted: May 12, 2022
Article in press: May 12, 2022
Published online: July 6, 2022
Processing time: 152 Days and 5.2 Hours
Core Tip

Core Tip: Lung cancer causes significant mortality worldwide. Patients with chronic renal failure increase the difficulty of treatment. Oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are effective treatment agents for non-small-cell lung cancer (NSCLC) patients. According to this review, EGFR-TKIs are suitable for treating NSCLC patients undergoing hemodialysis (HD) owing to their good response rates and tolerance. The main routes of elimination of EGFR-TKIs are via the liver and excretion via feces. The recommended doses and pharmacokinetics of EGFR-TKIs for patients undergoing HD are similar to those with normal renal function. The plasma protein binding of EGFR-TKIs is high, and it is not necessary to adjust the dose after HD.